(Total Views: 299)
Posted On: 09/09/2019 4:31:07 PM
Post# of 36549
Just bringing Oralyn and a 1-2 puff treatment for Type II diabetes should be enough to keep patients, health professionals, and investors excited. That's why many of us invested in Generex, aside from a little bird flu catalyst.
However, Generex in the mix for developing a cure for Type I diabetes? That's hard to wrap your mind around. Rich Purcell sounded way more excited about this development than I would have expected.
Unfortunately, there wasn't enough time to have Dr. EvH discuss AE 37, nor was there time to promote the NGIO shares. Joe didn't even have a chance to lay out the 1:1 dividend with the 10/30/2019 ex-div. date.
The presentation was short and definitely had some technical difficulties. I expect a more thorough PR tomorrow (?). I don't know if they had enough time to tell enough of the story to attract major investors. Joe will know soon enough, I guess.
Rich Purcell:
Richard Purcell - Senior Vice-President of Research & Drug Development
Mr. Purcell has over 30 years of experience in consulting and advising emerging biopharmaceutical and technology companies on new business strategy, operations management, clinical development of novel compounds, data solutions for clinical and medical applications, patient engagement & communication, medical education for professionals and consumers, and data analytics for outcomes research. Mr. Purcell oversaw strategic planning, clinical operations, data management, regulatory filings, and R&D and was involved with business development and out-licensing activities for the company’s technology platform.
He started his career as a molecular biologist, where he developed and patented a second generation TPA with increased half-life. He also worked at a major pharmaceutical company where he conducted primary research and published several manuscripts on the topics of AIDS and immunomodulators. Mr. Purcell also headed the Life Sciences Consulting Group for Kline and Company, where he conducted market, technology and business analysis for the commercial development of pharmaceutical and biotechnology products for therapeutic and diagnostic applications.
Rich graduated with a degree in Biochemical Sciences from Princeton University, and attended Rutgers Graduate School of Management majoring in marketing and finance. He is a member of NJTC, HIMSS, the Patient-Centered Primary Care Collaborative, the Drug Information Association and the Licensing Executives Society. He is also an Adjunct Professor of Biology at Monmouth University where he developed and teaches The Business of Biotechnology.
However, Generex in the mix for developing a cure for Type I diabetes? That's hard to wrap your mind around. Rich Purcell sounded way more excited about this development than I would have expected.
Unfortunately, there wasn't enough time to have Dr. EvH discuss AE 37, nor was there time to promote the NGIO shares. Joe didn't even have a chance to lay out the 1:1 dividend with the 10/30/2019 ex-div. date.
The presentation was short and definitely had some technical difficulties. I expect a more thorough PR tomorrow (?). I don't know if they had enough time to tell enough of the story to attract major investors. Joe will know soon enough, I guess.
Rich Purcell:
Richard Purcell - Senior Vice-President of Research & Drug Development
Mr. Purcell has over 30 years of experience in consulting and advising emerging biopharmaceutical and technology companies on new business strategy, operations management, clinical development of novel compounds, data solutions for clinical and medical applications, patient engagement & communication, medical education for professionals and consumers, and data analytics for outcomes research. Mr. Purcell oversaw strategic planning, clinical operations, data management, regulatory filings, and R&D and was involved with business development and out-licensing activities for the company’s technology platform.
He started his career as a molecular biologist, where he developed and patented a second generation TPA with increased half-life. He also worked at a major pharmaceutical company where he conducted primary research and published several manuscripts on the topics of AIDS and immunomodulators. Mr. Purcell also headed the Life Sciences Consulting Group for Kline and Company, where he conducted market, technology and business analysis for the commercial development of pharmaceutical and biotechnology products for therapeutic and diagnostic applications.
Rich graduated with a degree in Biochemical Sciences from Princeton University, and attended Rutgers Graduate School of Management majoring in marketing and finance. He is a member of NJTC, HIMSS, the Patient-Centered Primary Care Collaborative, the Drug Information Association and the Licensing Executives Society. He is also an Adjunct Professor of Biology at Monmouth University where he developed and teaches The Business of Biotechnology.
(2)
(0)Scroll down for more posts ▼
